PETVIVO HOLDINGS INC WTS - PETVW STOCK NEWS

PetVivo Holdings, Inc. (NASDAQ: PETV, PETVW) will exhibit its lead product, SPRYNG^™ with OsteoCushion^™ Technology, at the Western Veterinary Conference from March 6-9, 2022. SPRYNG is an injectable device designed to alleviate lameness and joint-related issues in pets, especially osteoarthritis. The conference is expected to attract over 15,000 participants, providing PetVivo with a key opportunity for networking and commercialization. The company aims to leverage its innovative veterinary solutions to enhance treatment options for companion animals.

PetVivo Holdings, Inc. (Nasdaq: PETV) reported financial results for the three and nine months ending December 31, 2021. Revenue for Q3 2022 was $51,004, a significant increase from $507 in Q3 2021, driven by sales of Spryng™. However, the net loss rose to $1,642,129, or ($0.17) per share, compared to a net loss of $1,037,753, or ($0.16) per share, the previous year. Total revenues for the nine months reached $60,126, up from $7,303 in 2020. Despite the revenue growth, increased costs in sales, marketing, and general administration contributed to a wider net loss.

PetVivo Holdings, Inc. (NASDAQ: PETV and PETVW) will announce its financial results on February 10, 2022, post-market close, followed by a conference call at 4:00 p.m. CT. Investors can register and access the live webcast through the company’s Investor Relations website. PetVivo focuses on innovative biomedical devices for animals, with a pipeline of 17 products and 21 patents, including its lead product, SPRYNG™, for treating osteoarthritis in dogs and horses. Disclosure of material nonpublic information will be made through its website and official communications.

PetVivo Holdings, Inc. (NASDAQ: PETV, PETVW) will announce its financial results on February 10, 2022, after market close. A conference call is scheduled for the same day at 4:00 p.m. CT (5:00 p.m. ET), with a live webcast available on their Investor Relations website. The company focuses on innovative medical therapeutics for animals and holds a portfolio of 21 patents. Their lead product, SPRYNG™, designed for treating osteoarthritis in dogs and horses, was commercially launched in September 2021.

PetVivo Holdings is set to present at the Emerging Growth Conference on January 19, 2022, from 11:30 AM to 12:00 PM Eastern. During this interactive session, CEO John Lai will discuss the company’s innovative biomedical devices for pets and answer audience questions. The conference aims to connect public companies with investors and includes a wide range of growth sectors.

PetVivo focuses on launching medical therapeutics for companion animals, with its lead product, Kush, targeting osteoarthritis in dogs and horses, anticipated for commercial release later this year.

PetVivo Holdings, Inc. (NASDAQ: PETV, PETVW) announces its participation in the Veterinary Meeting & Expo Conference from January 15-19, 2022, in Orlando, FL. The company will showcase its lead product, Spryng^™ with OsteoCushion^™ Technology, designed to treat joint issues in pets, particularly osteoarthritis. With over 7,500 expected participants, the event presents an opportunity for PetVivo to network with industry leaders. The company's product is set for expanded commercial sales in Q4 2022.

PetVivo Holdings, Inc. (NASDAQ: PETV, PETVW) has announced a distribution agreement with VetCove, Inc. to market its therapeutic product, SPRYNG™ with OsteoCushion™ Technology. VetCove, utilized by over 13,000 veterinary hospitals, will enable easier access for veterinarians to order SPRYNG for pets suffering from osteoarthritis. This innovative device, comprised of micronized hydrogel matrices, aims to support joint health and alleviates lameness. PetVivo also holds a diverse pipeline of products, enhancing its position in the veterinary market.

PetVivo Holdings, Inc. (NASDAQ: PETV & PETVW) will present at the H.C. Wainwright BioConnect Conference from January 10-13, 2022. CEO John Lai will discuss the company's business overview on January 10 at 12:00 PM EST. PetVivo focuses on innovative medical devices for pets, including its lead product, SPRYNG, which targets joint issues in animals. The company holds 21 patents and plans for expanded commercial sale of SPRYNG in Q4 2022. For more details, visit PetVivo's official website.

PetVivo Holdings, Inc. (NASDAQ: PETV, PETVW) announced a successful showcase of its product, Spryng^™, at the American Association of Equine Practitioners (AAEP) conference from December 4-8, 2021. Spryng utilizes OsteoCushion^™ Technology for treating lameness and joint issues like osteoarthritis. The company received positive feedback from veterinarians, indicating strong interest in adopting Spryng. PetVivo is offering a promotional deal through December 31, 2021, providing an extra syringe for every five purchased. The company plans expanded sales of Spryng in Q4 2021.